The No Pain Act will mandate Medicare insurance coverage for non-opioid pain management, including evidence-based treatments, ...

The Company announced the appointment of new members to its Board of Directors to help guide its next phase of growth and innovation, including ...

The cystic fibrosis treatment leader's revenue and earnings exceeded expectations. Vertex Pharmaceuticals is renowned for its leadership in the cystic fibrosis market. Its core product ...

Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for DMD at 2024 World ...

Palantir, Microchip Technology, and Arm Holdings are among the technology firms reporting this week, while pharmaceutical ...

Crispr Therapeutics recently received FDA and EMA approval for Casgevy. Read why CRSP stock is compelling investment in the ...

Trinasolar has recently reached a significant milestone, delivering more than 1 GW of its Vertex N 720W series modules to the ...

The experience zone will allow enterprises to witness AI technologies and identify the optimal generative AI use cases.

Micron announced changes to its Board of Directors on Wednesday. Micron said Robert (Bob) Switz, its current Board Chair, ...

William Blair analyst Myles Minter in a Monday note to investors said that Vertex’s povetacicept “has maintained its ...

Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior year period. The increase in research and development expense was primarily ...